SUMMARY. Chaga's disease is an important communicable neglected disease that is gaining wider attention due to its increasing incidence worldwide. Achalasia due to chagasic megaesophagus (CM), a complication of this disease, is a known-yet, poorly understood-etiological factor for esophageal squamous cell carcinoma (ESCC) development. In this study, we aimed to perform the analysis of TP53 mutations in a series of Brazilian patients with ESCC that developed in the context CM (ESCC/CM), and to compare with the TP53 mutation profile of patients with benign CM and patients with nonchagasic ESCC. Additionally, we intended to correlate the TP53 mutation results with patient's clinical pathological features. By polymerase chain reaction (PCR) followed by direct sequencing of the hotspot regions of TP53 (exon 5 to 8), we found that TP53 mutations were present in 40.6% (13/32) of the ESCC/CM group, 45% (18/40) of the nonchagasic ESCC group, and in only 3% (1/33) of the benign CM group. Missense mutations were the most common in the three groups, yet, the type and mutated exon mutation varied significantly among the groups. Clinically, the groups exhibited distinct features, with both cancer groups (ESCC and ESCC/CM) been significantly associated higher consumption of alcohol and tobacco, older age, worse Karnofsky performance status, poor outcome than the patients with benign CM. No significant association was found between TP53 mutation profile and clinical-pathological features in any of the three groups. We describe first the time the analysis of TP53 mutations in ESCC that developed in the context of CM, and the observed high frequency of mutations, suggest that TP53 also plays an important role in the tumorigenic process of this unexplored etiological condition.
INTRODUCTION
Esophageal cancer is the eighth most common cause of cancer worldwide, the sixth most frequent cause of cancer death. 1 In Brazil, according to estimates from the Brazilian National Cancer Institute (INCA) for 2016, esophageal cancer appears as the 10th most common cause of cancer, with an estimated 10,810 new cases for the year 2016.
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Esophageal cancer has two main histological types: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EADC). 3 These two histological types differ in both incidence trends and etiological factors. ESCC is the most frequent histological subtype in less developed countries, being tobacco use and alcohol consumption, followed by drinking hot beverage and nutritional deficiencies, the major risk factors. 1, [3] [4] [5] In contrast, EADC represents up to 50% of esophageal cancer cases in Western countries and its incidence has been rapidly increasing, mostly explained by increasing in prevalence of obesity and other lifestyle-associated factors. 1, 3 In Brazil, ESCC is the most frequent histological subtype, due to the abovementioned etiological agents. 6, 7 Interestingly, in the southeast region of Brazil, the high prevalence of megaesophagus and achalasia due to Chagas disease has been also described as another predisposition factor for ESCC development. [8] [9] [10] Achalasia is an esophageal motility disorder characterized by aperistalsis of the esophageal body and failure of lower esophageal sphincter relaxation, which lead to esophageal dilatation or megaesophagus and progressive dysphagia in affected patients. 11 The pathogenesis of achalasia is poorly understood and Chagas disease is the only proven etiological factor for achalasia. [12] [13] [14] Chagas disease, which is triggered by Trypanosoma cruzi infection, affects approximately 16 million people in Latin America and Caribbean. 15 Today, Chagas disease also affects other nonendemic regions of the world, due to migration, with several infected cases notified in countries such as Spain, the United States, Canada, Australia, and Japan. 15 It is estimated that in Brazil, between 3 and 4 million people are infected, with some endemic regions, mainly in rural areas with 3,6 deaths per 100.000 inhabitants/year in the last 30 years. 16, 17 The initial association of megaesophagus with ESCC risk factor was reported by Fagge in the XIX century. 18 Following this observation, several studies showed that patients with megaesophagus exhibited an increasing risk of 3.9%-10% of ESCC development, when compared to the normal population. 8, 19, 20 The pathophysiological mechanism of development of ESCC in patients with CM is poorly understood. It is believed to be due the parasitic destruction of neurons intramural myenteric, which leads to hypertrophy of the smooth muscle cells and increased connective tissue and thickening of the esophagus wall (megaesophagus), with consequent food stasis and inflammation, acanthosis, hyperkeratosis, and leucoplakia, some of them considered as probably premalignant conditions for ESCC. 8, [19] [20] [21] The studies evaluating the molecular mechanisms underlying this carcinogenic process are scarce.
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TP53 tumor suppressor gene exhibited a major role in the tumorigenesis of ESCC. 23 TP53 is, by far, the highest mutated gene, with frequencies varying between studies and population, and recently, whole genome sequencing analysis, confirm the high frequency (≈60%) of TP53 mutations. 24 In Brazil, it is been reported that approximately 35% of ESCC exhibited TP53 mutations. 25 In the present study, we aimed to interrogate the TP53 mutation status in a series of ESCC that develops in patients with chagasic megaesophagus (CM). We further intended to compare with the TP53 mutation profile of patients with benign CM and with patients with nonchagasic ESCC. Furthermore, we will correlate the TP53 mutation profile with patient's clinical pathological features.
MATERIALS AND METHODS

Study population
In this retrospective study, we analyzed 126 patients treated between 1990 and 2012 at three Brazilian hospitals from the southeast of Brazil: Hospital Of the 126 patients, we were not able to perform the TP53 mutation analysis in 21 patients, due to absence of available tumor tissue or poor quality of the obtained DNA. The remaining 105 patients were divided in three groups: (i) 32 patients with ESCC associated with chagasic megaesophagus confirmed by histopathologic and radiologic reports, and positive serology for Chagas disease (denominated ESCC/CM); (ii) 33 patients with radiological and histopathological confirmation of chagasic megaesophagus without ESCC (benign chagasic megaesophagus) and positive serology for Chagas disease (denominated CM); and (iii) 40 patients with ESCC without the presence of chagasic megaesophagus and negative serology for Chagas disease (denominated ESCC). Patients previously treated with chemotherapy or radiotherapy and without Chagas serology or tomography were not included in the study. This study was approved by the local ethic committees (409/2010). 
DNA isolation
Formalin-fixed paraffin-embedded (FFPE) tumors and tissue representative of the lesions were retrieved from the Department of Pathology of the respective hospitals, and all cases were histopathologically reclassified. DNA was obtained from FFEP sections as previously described, with some modifications. 26 Briefly, serially 10 μm thick unstained sections of paraffin blocks were sectioned, with one H&E section for identification and selection of the selected portion (ESCC/CM-tumor tissue; CMmegaesophagus tissue; and ESCC-tumor tissue). Selected areas were macrodissected into a microfuge tube using a sterile needle (Neolus, 25 G -0.5 mm). The macrodissected tissue was deparaffinized by a serial extraction with xylol and ethanol (100%-70%-50%) and allowed to air dry. DNA was extracted using Qiagen's QIAamp DNA Micro Kit following manufacture instructions and quantified by NanoDrop R 2000 (Thermo Scientific). DNA samples were stored at −20
• C until further genetic analysis.
TP53 mutation analysis
Analysis of hotspot mutations of TP53 (exons 5 to 8) was performed by polymerase chain reaction (PCR) followed by direct sequencing, as previously described by our group with some modifications. 27 The PCR reaction was carried out in a total volume of 15 μL, comprising 1 μL of DNA, 1× buffer solution, 2 mM MgCl2, 200 μM of each dNTPs, 0.3 μM of each primer (sense and antisense) and 0.5 U Taq DNA polymerase (Invitrogen). The primers sequenced used were previously described. 27 The PCR reaction was performed in a Veriti 96-Wll Thermal Cycler with an initial denaturation at 95
• C for 10 min, amplified for 40 cycles of denaturation at 95
• C for 45 seconds, annealing at 56
• C (exons 6 and 8) 57
• C (exon 5 and 7) for 45 seconds, extension at 72
• C for 45 seconds and a final extension at 72
• C for 10 minutes. The PCR products were applied in 2.0% agarose gel with GelRed (Biotium).
The PCR product was then submitted to direct sequencing using an ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit and analyzed an Genetic Analyzer ABI PRISM 3500 (Applied Biosystems). The chromatograms were compared to a TP53 reference sequence (Ensembl-ENSG00000141510). All samples that present any alterations were confirmed with at least two new PCR amplifications and sequencing.
Statistical analysis
All statistical analyses were performed using the SPSS software (Statistical Package for Social Science, v19.0). The characterization of the study population, including the results clinical-pathological, follow-up and molecular data were performed using descriptive statistics (for continuous variables: mean and standard deviation; for categorical variables: frequencies and percentages), presented in the form of tables. The associations of qualitative variables were performed using tests of association by the chi-square or Fisher's exact test. In the analysis of quantitative variables were used analysis of variance (when comparing three groups) and Student's t test (when comparing 2 independent groups), assuming a significance level of 5%. Overall survival of the three groups of patients was calculated employing the product limit estimator of the Kaplan-Meier method using the log-rank test to compare survival curves.
RESULTS
The major clinical-pathological features of the three groups of patients are summarized on Table 1 . Some characteristics were significantly different between all groups: patients with ESCC/CM and ESCC are older, exhibited a worse Karnofsky performance status, and showed a poor outcome than the patients with only CM (Table 1) . We also observed a significant higher consumption of alcohol and tobacco in both cancer groups (ESCC and ESCC/CM), than in CM patients without cancer (Table 1) . Molecularly, the presence of nonsynonymous (silent mutations excluded) TP53 mutations was observed in 32 patients (Table 2 and Fig. 1 ). We found TP53 mutations in 13/32 (40.6%) ESCC/CM patients and in 18/40 (45%) ESCC patients. In the ESCC/CM group, two patients (ID129 and ID130) exhibited two distinct mutations (Table 2) . Only one (3%, 1/33) CM patient showed the presence of TP53 mutation ( Table 2) .
The TP53 mutation frequency was statistically significantly different between the three groups (P < 0.001) (Table 3) , mainly due to the low prevalence of TP53 mutation observed in the CM group, when compared to the ESCC/CM and ESCC (Table 3) . We further compared the distribution of TP53 mutations by different exons in the three groups (Table 3 ). In the two groups of patients suffering from cancer (ESCC/CM and ESCC), mutations occurred in all 4 exons and in the CM group, the only mutation observed was on exon 5 (Table 3 ). In the ESCC/CM group and ESCC exons 5 and 8 were equally affected (15.6% and 10% respectively). Regarding the nature of the mutations, missense mutations were the most prevalent in all three groups (Table 3) .
Moreover, the correlation of TP53 mutation profile with patients clinical-pathological features indicates the absence of any significant association (Table 4) . We also compared the overall survival curves between TP53 mutated (red colour) and wild-type (blue colour) patients in each group and no significant differences (P = 0.175) were reported (Fig. 2) .
In order to evaluate the potential carcinogenic fingerprinting of each patient group, we considered all nonsynonymous and synonymous (silent) mutations (Table 5 and Fig. 3 ). We observed that in the ESCC group, the most frequent type of mutation was G:C→A:T in the CpG (31.8%), followed by G:C→A:T non CpG (27.4%) and G:C→T:A (22.3%). In group ESCC/CM, the most frequent mutation was A:T→T:A (25%) and G:C→T:A (25%), followed by CM, chagasic megaesophagus; ESCC, squamous cell carcinoma of the esophagus; ESCC/CM, squamous cell carcinoma of the esophagus associated with chagasic megaesophagus; Mut, mutant; NA, not applicable; SD, standard deviation; WT, wild-type. deletions (18.8%). In the CM group, all six mutations identified (1 nonsynonimous and 5 synonimous) were G:C→A:T non CpG (100%) ( Table 5 and Fig. 3 ).
DISCUSSION
Chagasic megaesophagus (CM), a complication of Chagas disease, is considered a predisposition condition for the development of ESCC. 8, 19, 20 Despite this known association, the molecular mechanisms underlying ESCC development in patients with CM are unexplored. Such studies are of particular relevance for Latin America and Brazil, where the Chagas disease is still endemic in some regions and represents an important health problem. 15 Herein, we investigate for the first time the profile of TP53 mutation in ESCC associated with CM (ESCC/CM) and compare it with the molecular profile of ESCC not associated with megaesophagus and with the benign CM. We showed that 40.6% of the ESCC that develop in the context of CM harbor TP53 mutations, which was similar to the ESCC group (45%) and statistically superior to CM group (3%). The high frequency of TP53 mutations in the ESCC/CM group suggests that TP53 is also a key player in tumorigenesis of ESCC in the context of Chagas disease, as it has been widely accepted for ESCC. 24 The presence of TP53 mutation in CM patients, albeit at a significant lower frequency, may mean that the TP53 mutation occurs already in premalignant lesions. Interestingly, a previous study analyzed a series of CM, also from the same region of the present study, for the presence of genomic imbalances in genes relevant in esophageal carcinogenesis, and any significant event was observed. 22 So, TP53 mutations in the conjugation other etiological factors may contribute to cancer development. In fact, our observation of a higher consumption of alcohol and tobacco observed in the ESCC/CM group in comparison with the CM group, supported this hypothesis. Nevertheless, further studies, using prospective epidemiological and case-control designed approaches and involving a higher number of patients are warranted to clarify this issue. We observed slightly higher frequency (40.6%) of TP53 mutations in the ESCC without CM group, than previous published for Southern (34.8%) and Southeast (34.5%) Brazilian population, 25, 28 and relatively lower then what reported for countries with high incidence of ESCC, such as China (42%-77%) and Iran (50%-90%). 29, 30 These differences in ESCC TP53 mutation frequencies observed worldwide may be associated with multiple factors, including different exposure agents, different population and different methodologies issues.
The TP53 gene is frequently mutated in human tumors. 23 The majority of these mutations are missense and occur between exons 5-8 leading to a functional inactivation of cellular protein. 23 According to the IARC TP53 mutation database, the hotspotsTP53 codons in ESCC of the esophagus are 170, 175, 179, 193, 220, 245, 248, 273, and 282. 31 Most mutations identified in our cases were in codons 151 and 275 (with three mutations each codon), followed by codons 195, 196, 248, 273, 282 , and 285 (with two mutations each codon). Although is not usually considered to be a hotspot codon, mutation at position 151 leads to a structural alteration, which results in significant functional changes in the p53 protein that impact tumor progression. 32 Although codon 275 is not common referred to as hotspot mutations, the Cys275Phe found in our cases is reported as a deleterious somatic mutation that leads to loss of protein function. 31 Besides the biological consequence, the analysis of TP53 mutations allows interrogating about the potential carcinogenic agent who operated in each case, and therefore to understand the biological mechanisms that drive in malignant transformation. In other words, the mutation spectrum analysis can function as a molecular fingerprint of the agent that causes DNA damage. 33 The results of this study showed that the most frequent type of mutation in the ESCC group was G:C→A:T (CpG) (31.8%), followed by G:C→A:T at non CpG sites (27.4%) and G:C→T:A (22,3%) . The transversion G:C→T:A mutations have been frequently detected in lung tumors from heavy smokers and experimentally associated with DNA adduct formation by B[a]P metabolites. 34, 35 The G:C→A:T transitions at non CpG sites are associated with both acetaldehyde and nitrosamines, 34 so there is a concordance between the identified risk factors (alcohol and tobacco). This type of mutations is the most frequently described in CE. 36 In CM group, mutation type observed in all cases was a G:C→A:T, as described above associated with acetaldehyde and nitrosamines. 34 These latter agents are important compounds derived from food stasis observed inside the megaesophagus. 37 Finally, the most prevalent mutations in the group ESCC/CM are G:C→T:A and A:T→T:A, being the mutation G:C→T:A associated with benzopyrene (tobacco) 34, 35 and the A:T→T:A mutation are associated with acetaldehyde. 38 The high prevalence rates of these mutations in ESCC/CM patients, further suggests that smoking and alcohol are important cofactors for the development of ESCC in patients with CM.
In conclusion, we observed a high frequency of TP53 mutation in ESCC/CM, suggesting the central role of TP53 the development of this unknown and neglected tumor. Future studies will be important to validate and extend these important findings that may contribute to the elucidation of the carcinogenic pathway of ESCC associated with chagasic megaesophagus.
